Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Biotechnology

Healthcare
$2.82 -1.97%

-$0.24 today

Market cap
$54.80M
Beta
1.68
P/E (TTM)
-1.1
EPS (TTM)
-$10.75
52W Low $10.03High $69.97

Volume 1.04M

Average 0.49M

TNXP Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $28.07M rose 177.8% year over year, ahead of the +90.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 20.2% from the prior quarter. Over 3 fiscal years it compounded at +41.6% a year.

Context

  • Selling, general & admin amounted to 654.3% of revenue in FY2025, up 257.0 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of $194.3M (+126.6%) for the fiscal year ending Dec 2026, a step up from the +113.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$28.07M-20.2% QoQ
Last fiscal yearDec 2025
$85.76M+113.9% YoY
LTMMar 2026
$63.26M+90.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+177.8%——
1 year+113.9%+126.6%+12.7 pp
3-year CAGR+41.6%+94.5%+53.0 pp
5-year CAGR+65.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
85.76M USD
Year-over-year change
+113.9%
4-year CAGR
+38.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How TNXP compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +90.6% is the highest of 10, against a peer median of -15.6%.
  • Selling, general & admin amounts to 360.3% of revenue for TNXP, versus a peer median of 1952.5%.
TNXP Competitors
Selling, General & Admin for TNXP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$63.26M USD+90.6%+41.6%360.3%
FATEFate Therapeutics, Inc.LTM Mar 2026$42.34M USD-49.3%-18.0%670.4%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$35.34M USD-27.5%-17.7%3080.9%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$34.83M USD-4.4%-11.4%1952.5%
NKTXNkarta, Inc.LTM Mar 2026$25.06M USD-19.7%+4.0%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$24.19M USD+23.5%+3.4%41000.0%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$16.54M USD-15.6%+10.2%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$13.7M USD+20.3%+31.5%—
IPHAInnate Pharma S.A.FY2025€11M EUR-7.8%-8.7%394.7%
FBRXForte Biosciences, Inc.LTM Mar 2026$10.95M USD-28.8%+14.3%—
Peer median (excluding TNXP) —-15.6%+3.4%1952.5%

Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue007.77M10.09M13.11M
Cost of Revenue004.74M7.77M8.57M
Gross Profit003.03M2.33M4.54M
Gross Margin——39.0%23.1%34.7%
Research & Development68.84M81.88M86.66M40.45M44.49M
Selling, General & Admin23.47M30.22M34.75M40.1M85.76M
Operating Expenses92.31M112.09M121.41M139.03M130.25M
Depreciation & Amortization50K1.25M4.29M3.42M1.93M
EBITDA(92.24M)(108.97M)(112.37M)(74.32M)(122.01M)
EBITDA Margin——-1446.5%-736.3%-930.9%
Operating Income(92.31M)(112.09M)(118.38M)(136.7M)(125.7M)
Operating Margin——-1523.9%-1354.3%-959.1%
Interest Income25K1.87M004.15M
Interest Expense000089K
Other Income / Expenses25K1.87M1.72M6.67M1.68M
Income Before Tax(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Pre-Tax Margin——-1501.8%-1288.3%-946.2%
Income Tax Expense00000
Net Income(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Net Margin——-1501.8%-1288.3%-946.2%
EPS (Basic)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
EPS (Diluted)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
Weighted Avg Shares5633.07M1.83M2.26M8.51M
Weighted Avg Shares (Diluted)5633.07M1.83M2.26M8.51M

Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.